Predictmedix Announces Third-Party Independent Clinical Validation for AI-Powered Screening following 400 Patient Study at MGM Healthcare
February 15 2023 - 8:30AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2023/2/15/aiiumScreenshot_2023-02-15_at_13.28.46.png)
Predictmedix Announces Third-Party
Independent Clinical Validation for AI-Powered Screening following
400 Patient Study at MGM Healthcare
Toronto, Ontario, February 15, 2023 --
InvestorsHub NewsWire -- Predictmedix Inc. ("Predictmedix" or the
"Company") (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP), an emerging provider of rapid
health screening solutions powered by a proprietary artificial
intelligence (AI), today announced pivotal clinical validation data
from one of the largest Government hospital groups in India for the
company's AI-powered Safe Entry Stations. The third-party clinical
findings show that Predictmedix's Safe Entry Stations accurately
screen for various physiological conditions non-invasively – a
pivotal milestone for the company's proprietary technology
portfolio and for the global healthcare industry.
"Our team is diligently working
towards the goal of Safe Entry being in thousands of hospital
triages across the world. We believe our technology will
drastically improve patient care and reduce the strain on already
over-extended healthcare workers, " commented Dr. Rahul Kushwah,
Chief Operating Officer at Predictmedix. "We're thrilled with the
successful clinical findings from MGM Healthcare and are
aggressively moving forward with commercializing Safe Entry as an
automated, non-invasive healthcare tool powered by artificial
intelligence."
The scope of the study was to
determine the effectiveness of Predictmedix's AI-powered screening
technology. The Safe Entry Station is a walk-thru system where an
individual stands in front of the unit for 2-3 seconds while the
multi-spectral imaging cameras gather the necessary information to
determine the physiological state of the individual. Parameters
like temperature, heart rate and respiration rate are collected
non-invasively and the AI/ML algorithms compute a result. Vitals
hold key insight into an individual's state, whether they're
dealing with health complications, influenza, fatigue or even
impairment. Safe Entry does not capture or store personal identity
information, ever.
"The team at MGM has found Safe Entry
to be ideal for hospital settings to non-invasively screen patients
for various conditions by checking vital signs. We found Safe Entry
to be very accurate at reading vital signs such as temperature,
heart rate and respiration rate. Our overall assessment of Safe
Entry has been quite positive as it has been used in various
settings during the peak of the Covid outbreak within our hospital.
Safe Entry was deployed at MGM for over 18 months, making several
upgrades to their AI algorithms and models and now reached a mature
stage of commercialization," read the independent clinical report
from MGM dated February 2023.
MGM Healthcare is one of the largest
groups of medical universities in India encompassing several
hospitals across India. MGM's state-of-the-art hospitals and
centres of care focus on rebuilding lives and providing outstanding
healthcare to its patients. To learn more about MGM Healthcare,
please visit
https://mgmhealthcare.in/.
About Predictmedix
Inc.
Predictmedix (CSE: PMED) (OTCQB:
PMEDF) (FRA:3QP) is an emerging provider of rapid health screening
and remote patient care solutions globally. The Company's Safe
Entry Stations - powered by a proprietary artificial intelligence
(AI) - use multispectral cameras to analyze physiological data
patterns and predict a variety of health issues including
infectious diseases such as COVID-19, impairment by drugs or
alcohol, fatique or various mental illnesses. Predictmedix's
proprietary remote patient care platform empowers medical
professionals with a suite of AI-powered tools to improve patient
health outcomes. To learn more, please visit our website at
www.Predictmedix.com or follow us on Twitter, Instagram or
LinkedIn.
Public Relations
Contact
For further media information or to
set up an interview, please contact:
Nelson Hudes
Hudes Communications
International
(905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah
(647) 889 6916
Caution Regarding
Forward-Looking Information:
This news release may contain
forward-looking statements and information based on current
expectations. These statements should not be read as guarantees of
future performance or results of the Company. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by such statements.
Although such statements are based on management's reasonable
assumptions, there can be no assurance that such assumptions will
prove to be correct. We assume no responsibility to update or
revise them to reflect new events or circumstances. The Company's
securities have not been registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or applicable
state securities laws, and may not be offered or sold to, or for
the account or benefit of, persons in the United States or "U.S.
Persons", as such term is defined in Regulations under the U.S.
Securities Act, absent registration or an applicable exemption from
such registration requirements. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of the securities in the United States
or any jurisdiction in which such offer, solicitation or sale would
be unlawful. Additionally, there are known and unknown risk factors
which could cause the Company's actual results, performance or
achievements to be materially different from any Page 4 of 4 future
results, performance or achievements expressed or implied by the
forward-looking information contained herein, such as, but not
limited to dependence on obtaining regulatory approvals; the
ability to obtain intellectual property rights related to its
technology; limited operating history; general business, economic,
competitive, political, regulatory and social uncertainties, and in
particular, uncertainties related to COVID-19; risks related to
factors beyond the control of the Company, including risks related
to COVID-19; risks related to the Company's shares, including price
volatility due to events that may or may not be within such party's
control; reliance on management; and the emergency of additional
competitors in the industry.
All forward-looking information herein
is qualified in its entirety by this cautionary statement, and the
Company disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except
required by law.
Disclaimer: "The Company is not making
any express or implied claims that its product has the ability to
diagnose, eliminate, cure or contain the COVID-19 (or SARS-2
Coronavirus) at this time."
THE CANADIAN SECURITIES EXCHANGE HAS
NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
Predictmedix Al (CSE:PMED)
Historical Stock Chart
From Jul 2024 to Aug 2024
Predictmedix Al (CSE:PMED)
Historical Stock Chart
From Aug 2023 to Aug 2024